scholarly journals Induction therapy in kidney transplant recipients: Description of the practices according to the calendar period from the French multicentric DIVAT cohort

PLoS ONE ◽  
2020 ◽  
Vol 15 (10) ◽  
pp. e0240929
Author(s):  
Julie Boucquemont ◽  
Yohann Foucher ◽  
Christophe Masset ◽  
Christophe Legendre ◽  
Anne Scemla ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Induction Therapy ◽  
Calendar Period ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Immunosuppressive Management of Pediatric Kidney Transplant Recipients

2020 ◽  
Vol 26 (28) ◽  
pp. 3451-3459
Author(s):  
Tomáš Seeman
Keyword(s):  
Immunosuppressive Therapy ◽  
Kidney Transplant ◽  
Induction Therapy ◽  
Graft Loss ◽  
Calcineurin Inhibitors ◽  
Mtor Inhibitors ◽  
Therapeutic Drug ◽  
High Dose ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

: Kidney transplantation is a preferable treatment of children with end-stage kidney disease. All kidney transplant recipients, including pediatric need immunosuppressive medications to prevent rejection episodes and graft loss. : Induction therapy is used temporarily only immediately following transplantation while maintenance immunosuppressive drugs are started and given long-term. There is currently no consensus regarding the use of induction therapy in children; its use should be decided based on the immunological risk of the child. : The recent progress shows that the recommended strategy is to use as maintenance immunosuppressive therapy a combination of a calcineurin inhibitor (preferably tacrolimus) with an antiproliferative drug (preferably mycophenolate mofetil) with steroids that can be withdrawn early or late in low-risk children. The mTOR-inhibitors (sirolimus, everolimus) are used rarely in pediatrics because of common side effects and no evidence of a benefit over calcineurin inhibitors. The use of calcineurin inhibitors, mycophenolate, and mTOR-inhibitors should be followed by therapeutic drug monitoring. : Immunosuppressive therapy of acute rejection consists of high-dose steroids and/or anti-lymphocyte antibodies (T-cell mediated rejection) or plasma exchange, intravenous immunoglobulines and/or rituximab (antibodymediated rejection). : The future strategies for research are mainly precise characterisation of children needing induction therapy, more specific indications for mTOR-inhibitors and for the far future, the possibility to reach the immuno tolerance.

Role of induction therapy in low immunological risk-kidney transplant recipients: A mate-kidney analysis

2019 ◽  
pp. e13442 ◽  
Author(s):  
Kalathil K. Sureshkumar ◽  
Vinaikumar Katragadda ◽  
Bhavna Chopra ◽  
Marcelo Sampaio
Keyword(s):  
Kidney Transplant ◽  
Induction Therapy ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals Optimal Dose of Thymoglobulin for Induction Therapy in High Risk Kidney Transplant Recipients

2016 ◽  
Vol 30 (2) ◽  
pp. 82
Author(s):  
Yaerim Kim ◽  
Seong Sik Kang ◽  
Woo Yeong Park ◽  
Kyubok Jin ◽  
Sung Bae Park ◽  
...  
Keyword(s):  
High Risk ◽  
Kidney Transplant ◽  
Induction Therapy ◽  
Optimal Dose ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Induction Therapy with Basiliximab versus Thymoglobulin in African-American Kidney Transplant Recipients

2005 ◽  
Vol 79 (6) ◽  
pp. 716-721 ◽  
Author(s):  
Abdolreza Haririan ◽  
Katherina Morawski ◽  
Dale H. Sillix ◽  
Jose M. El-Amm ◽  
James Garnick ◽  
...  
Keyword(s):  
African American ◽  
Kidney Transplant ◽  
Induction Therapy ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals Comparison of clinical outcome of induction immunosuppressive therapy with thymoglobulin and standard therapy in kidney transplantation; a randomized double-blind clinical trial

2019 ◽  
Vol 9 (1) ◽  
pp. e08-e08
Author(s):  
Heshmatollah Shahbazian ◽  
Ali Ghorbani ◽  
Fatemeh Hayati ◽  
Seyed Seifollah Beladi Mousavi ◽  
Leila Sabetnia ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Kidney Transplantation ◽  
Kidney Transplant ◽  
Induction Therapy ◽  
Allograft Rejection ◽  
Control Group ◽  
Case Group ◽  
Transplant Recipients ◽  
Acute Allograft Rejection ◽  
Kidney Transplant Recipients

Introduction: Thymoglobulin is a lymphocyte-depleting polyclonal antibody, administered for induction therapy at the time of kidney transplantation to reduce the risk of acute allograft rejection. The appropriate dosage and duration of therapy is controversial. The higher dosages are associated with infection and malignancy. Objectives: In this study efficacy and safety of lower dosage (in comparison with previous studies) of thymoglobulin in kidney transplant recipients was evaluated. Patients and Methods: In this clinical trial, 106 adult kidney transplant recipients, were randomized before transplantation in two groups (case and control). The case group (53 patients) were received induction therapy with thymoglobulin (1.5 mg/kg/d for 3 days) and the control group (53 patients) were received non-induction regiment. Delayed graft function (DGF), glomerular filtration rate (GFR), acute allograft rejection and thymoglobulin complications were evaluated during the first post-transplantation year. Results: Around 106 kidney transplant recipients were enrolled (71 or 66.98% deceased donor) to the study. No significant statistical differences were found in GFR at the time of discharge from hospital (P=0.399) and at 1 year (P=0.851) and acute allograft rejection (P= 0.304) between two groups. Graft survival (73.5% in case group versus 81.1% in control group, P=0.392) at month 12th was similar among groups. Additionally, no significant differences of acute allograft rejection in recipient from deceased or living donor between two groups were detected. There was a higher incidence of DGF in the control group (26.4%) than the thymoglobulin group (5.8%) and the difference was statistically significant (P= 0.004). Thrombocytopenia (17% versus 49.1%, P<0.001) and leukopenia (11.3% versus 50.9%, P<0.001) were also significantly higher in the case group. Conclusion: While the incidence of DGF was reduced in thymoglobulin group, the short-term acute allograft rejection rate was not reduced compared to the control group. However, our results require further consideration with larger samples

Sign in / Sign up

Export Citation Format

Share Document